As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include an interesting publication from low- and middle-income countries.
Read Professor Hughes' CML publications of the month: August 2024
Clinical CML papers
- Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial
Gambacorti-Passerini C et al. Leukemia, August 2024 (epub ahead of print)
– open access publication - Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: Results from the ASCEND study
Yeung DT et al. Blood, August 2024 (epub ahead of print) - Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring
Jabbour E and Kantarjian H. Am J Hematol, August 2024 (epub ahead of print) – open access publication - Optimal frontline therapy of chronic myeloid leukemia today, and related musings
Kantarjian HM et al. Am J Hematol, August 2024 (epub ahead of print) – open access publication - Ponatinib review of historical development, current status, and future research
Kantarjian HM et al. Am J Hematol, August 2024 - Real-world outcomes of ponatinib treatment in 724 patients with CML and Ph+ ALL: a post-marketing surveillance study with a special interest in arterial occlusive events in Japan
Takahashi N et al. Jpn J Clin Oncol, August 2024 (epub ahead of print) – open access publication - Imatinib versus newer generation tyrosine kinase inhibitors for upfront therapy in chronic-phase chronic myeloid leukemia: What is the rationale for paying more to get the same survival benefit?
Lipton JH et al. Am J Hematol, August 2024 (epub ahead of print) – open access publication - A lower initial dose of bosutinib for patients with chronic myeloid leukemia resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 (BOGI) trial
Ureshino H et al. Int J Hematol, August 2024 (epub ahead of print) – open access publication - Presentation of chronic myeloid leukemia in basophilic blast crisis
Hazarika B and Bain BJ Am J Hematol, August 2024 (epub ahead of print) – open access publication - Does presence of complex translocations involving BCR::ABL1 in chronic myeloid leukemia affect the response rate to tyrosine kinase inhibitors? A systematic review of literature
Sharma D et al. Ann Diag Pathol, August 2024 - Comparable efficacy and safety of generic and branded imatinib for patients with chronic myeloid leukemia in China
Cheng F et al. Ther Adv Hematol, August 2024 – open access publication - BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib
Leyte-Vidal A. et al. Blood, August 2024 - Shedding light on resistance to asciminib (Comment on Leyte-Vidal et al)
Breccia M. Blood, August 2024 - Global trial representation and availability of tyrosine kinase inhibitors for treatment of chronic myeloid leukemia
Casey M et al. Cancers, August 2024 – open access publication
Scientific CML papers
- BCR::ABL1 proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of PH+ leukemias?
Cruz-Rodriguez N et al. Leukemia, August 2024 (epub ahead of print) – open access publication - Single-cell proteo-transcriptomic profiling reveals altered characteristics of stem and progenitor cells in patients receiving cytoreductive hydroxyurea in early-phase chronic myeloid leukemia
Komic H et al. Haematologica, August 2024 (epub ahead of print) – open access publication - Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
Fontana D et al. Leukemia, August 2024 – open access publication
LMIC CML papers
- Unveiling the nephrotoxic profile of BCR-ABL tyrosine kinase inhibitors:A real-world experience in Africa
Ayalew ZS et al. EJHaem, July 2024, eCollection Aug 2024 – open access publication